Recessive mutations account for a small fraction of CPVT patients and have been mainly associated with proteins regulating the RyR2 complex activity such as calsequestrin2 (CASQ2), triadin (TRDN) and trans-2,3-enoyl-CoA reductase-like (TECRL) [19,20,21]. The gene discussed is TECRL; the disease is catecholaminergic polymorphic ventricular tachycardia.